Sinopharm

Sinopharm’s China TCM buyout bid lapses without regulatory nods

CHINA National Pharmaceutical Group’s latest attempt to take China Traditional Chinese Medicine (TCM) Holdings private has fallen through as it was unable to secure necessary regulatory approval from ...

Sinopharm, the parent of China-TCM, already holds a 32.46 per cent stake in China-TCM and has offered to pay HK$4.6 (S$0.79) per share in cash to buyout the drugmaker.

Sinopharm offers to take China-TCM private in nearly US$3 billion deal

A consortium led by state-owned pharma giant Sinopharm has revived a take-private bid for China Traditional Chinese Medicine Holdings, the Hong-Kong-listed drugmaker said on Wednesday (Feb 21), valuin...